Data from Incyte’s Oncology Portfolio to be Featured at the 2019 ESMO Congress
3.9.2019 15:14:00 EEST | Business Wire | Press release
Incyte (Nasdaq:INCY) announces that abstracts highlighting data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain from September 27-October 1, 2019.
Results from FIGHT-202, a Phase 2 study of pemigatinib as a second-line treatment for patients with advanced/metastatic or surgically unresectable cholangiocarcinoma, including updated safety and efficacy data in patients with FGFR2 fusions or rearrangements, as well as genomic profiling and correlations with clinical outcomes will be presented. Results from the Phase 1 study of INCB001158, an arginase inhibitor being developed with Calithera Biosciences, alone and in combination with pembrolizumab as a treatment for advanced or metastatic solid tumors, will also be presented.
“Incyte is committed to advancing treatments that have the potential to address areas of high unmet need and we look forward to sharing data on our investigational therapies with the oncology community at ESMO 2019,” said Steven Stein, M.D., Chief Medical Officer, Incyte. “Data from the Phase 2 FIGHT-202 study assessing pemigatinib as a potential treatment for cholangiocarcinoma are encouraging and may represent an important step forward for patients in urgent need of effective treatment options.”
Abstracts will be available on the ESMO Congress website at https://www.esmo.org/Conferences/ESMO-Congress-2019.
Oral Presentations:
FIGHT-202: a Phase 2 study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA) (Abstract #2550, proffered paper session)
- Friday, September 27, 2019 from 3:00 p.m. CEST to 3:15 p.m. CEST (9 a.m. ET to 9:15 a.m. ET) in Madrid Auditorium (Hall 2)
Phase 1 study of the arginase inhibitor INCB001158 (1158) alone and in combination with pembrolizumab (PEM) in patients (Pts) with advanced/metastatic (Adv/Met) solid tumors (Abstract #1621, oral abstract session)
- Sunday, September 29, 2019 from 4:54 p.m. CEST to 5:06 p.m. CEST (10:54 a.m. ET to 11:06 a.m. ET) in Malaga Auditorium (Hall 5)
Poster Details:
Comprehensive genomic profiling and clinical outcomes in patients (pts) with fibroblast growth factor receptor rearrangement-positive (FGFR2+) cholangiocarcinoma (CCA) treated with pemigatinib in the FIGHT-202 trial (Abstract #2078, poster session)
- Sunday, September 29, 2019 from 12:00 p.m. CEST to 1:00 p.m. CEST (6:00 a.m. ET to 7:00 a.m. ET) in Poster Area (Hall 4)
Full session details and data presentation listings for ESMO 2019 can be found at: https://cslide.ctimeetingtech.com/esmo2019/attendee.
About Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s website at www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from the Company’s ongoing clinical development programs for pemigatinib and an arginase inhibitor as monotherapy and in combination with pembrolizumab and the potential of such programs, including the potential for pemigatinib to treat cholangiocarcinoma, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA; the Company’s dependence on its relationships with its collaboration partners; the efficacy or safety of the Company’s products and the products of the Company’s collaboration partners; the acceptance of the Company’s products and the products of the Company’s collaboration partners in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; greater than expected expenses; expenses relating to litigation or strategic activities; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-Q for the quarter ended June 30, 2019. The Company disclaims any intent or obligation to update these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190903005491/en/
Contact information
Incyte Contacts
Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com
Investors
Michael Booth, DPhil
+1 302 498 5914
mbooth@incyte.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe11.8.2026 14:30:00 EEST | Press release
Alfasigma S.p.A. (“Alfasigma”), a global pharmaceutical company, today announced that it has entered into a share purchase agreement with SEVER Life Sciences B.V. ("SEVER") for the sale of 100% of the shares of Nordic Group B.V. (“Nordic Pharma”) and its subsidiaries, a privately owned specialty pharmaceutical company with direct operations in Europe, Canada and Japan. The acquisition will add Nordic Pharma’s established rheumatoid arthritis business, led by the Nordimet® methotrexate franchise, to Alfasigma’s rheumatology portfolio, which includes the Jyseleca® franchise. It will also deepen Alfasigma’s commercial reach through direct operations in 18 countries across Europe and add commercial platforms in Canada and Japan. In addition to rheumatology, the acquisition includes Nordic Pharma’s portfolio in women’s health, critical care and ophthalmology. It also brings 265 employees with specialist capabilities and expertise. The transaction is subject to customary closing conditions,
Organigram Reports Record Third Quarter Fiscal 2026 Results11.8.2026 13:00:00 EEST | Press release
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share2 and a growing global cannabis platform following its acquisition of Sanity Group GmbH (“Sanity” or “Sanity Group”), today announced its results for the third quarter ended June 30, 2026 (“Q3 Fiscal 2026” or “Q3”). Q3 FISCAL 2026 HIGHLIGHTS Gross Revenue: $145.1 million (+32% year-over-year). Net Revenue: $105.8 million (+49% year-over-year). Adjusted EBITDA1: $13.4 million (+136% year-over-year). #1 Market Share in Canada: #1 in vapes, #1 in milled flower, #1 in concentrates, #2 in flower, #2 in pre-rolls, #3 in edibles, and #4 in beverages2. Sanity Group: Since the acquisition closed on April 15, 2026, Sanity has performed in line with management's expectations, contributing approximately €25 million (C$40 million) in net revenue to Organigram's consolidated results. During the quarter, Sanity continued to execute on its European growth strategy, advancing pr
L&T Technology Services Launches AgenticIQ™, an End-to-End Agentic AI Platform for Engineering, Manufacturing and Customer Experience11.8.2026 12:30:00 EEST | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), a global leader in Engineering Intelligence Solutions & ER&D Consulting Services, today announced the launch of AgenticIQ™, an end-to-end Agentic AI platform purpose-built for engineering and manufacturing organizations. Designed to help enterprises move beyond isolated AI pilots, AgenticIQ™ enables autonomous, multi-agent workflows across engineering, product development, manufacturing, industrial operations and customer experience, accelerating the adoption of Engineering Intelligence at scale. As enterprises increase investments in AI, many initiatives continue to struggle to move beyond proof-of-concepts into production. Disconnected engineering systems, manual processes and highly regulated environments often prevent organizations from scaling autonomous AI while maintaining governance, security and operational reliability. Built on LTTS' portfolio of Engineering Intelligence solutions, AgenticIQ™ transforms proven engineering capa
Naser Taher Named Among Forbes Middle East’s Top 100 CEOs 202611.8.2026 12:00:00 EEST | Press release
MultiBank Group, one of the world’s largest and most regulated financial derivatives institutions, has announced that its Founder and Chairman, Naser Taher, has been named among Forbes Middle East’s Top 100 CEOs 2026, recognising his longstanding leadership and achievements in the global financial services industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811229836/en/ Naser Taher has been named among Forbes Middle East’s Top 100 CEOs 2026, recognising his longstanding leadership and achievements in the global financial services industry. The annual Forbes Middle East Top 100 CEOs list celebrates prominent business leaders who are shaping the region’s corporate landscape and leading organisations with significant scale, influence and impact. The ranking brings together senior executives from across key industries in the Middle East, highlighting their leadership and the performance and development of the organisati
teamLab Unveils New Series from Light Sculpture - Flow at teamLab Borderless. Special Exhibit, "On the Asymmetry of the Universe," on View Through October 811.8.2026 12:00:00 EEST | Press release
teamLab reopens the Light Sculpture - Flow series artwork space at teamLab Borderless: MORI Building DIGITAL ART MUSEUM in Azabudai Hills, Tokyo from July 8, 2026. To commemorate the reopening, teamLab unveils two new series, Asymmetric Existence and Chromatic Existence, featured in the special exhibit "On the Asymmetry of the Universe." The special exhibit, “On the Asymmetry of the Universe,” runs from Wednesday, July 8, 2026 through Thursday, October 8, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260807256066/en/ Light Sculpture - Flow The inside and outside of an ocean vortex are composed of the same water; there is no material difference between them. Yet, despite this, why do we perceive a vortex as a singular entity, or even sense a form of life within it? The difference between the inside and outside of a vortex lies in the order, not the material. When order is born within a flow, existence emerges even with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom